Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization

NCT06550024 · View on ClinicalTrials.gov ↗

Study Summary

An open label, prospective, two-arm, multicenter, randomized controlled trial comparing SakuraBead genicular artery embolization (GAE) with a control (corticosteroid injection).

Interventions

  • DRUG Corticosteroid Injection
  • DEVICE SakuraBead Resorbable Microspheres

Study Locations (8)

Other

  • Bokhua Memorial Cardiovascular Center — Tbilisi
  • Royal Berkshire NHS Foundation Trust — Reading

Alabama

  • University of Alabama Medicine — Birmingham

California

  • Harbor UCLA Medical Center — Torrance

Florida

  • Advanced Vascular Institute — Panama City

North Carolina

  • IR Centers — Raleigh

Virginia

  • IR Centers — Leesburg

Uzbekistan

  • Nano Medical Clinic — Tashkent

Trial Details

FieldValue
Enrollment Target 89 participants
Start Date 2024-11-28
Est. Completion 2028-10
Phase NA

Sponsor

CrannMed

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06550024

The ClinicalTrials.gov registry entry for NCT06550024 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CrannMed, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 6 conditions, with Osteoarthritis appearing as the primary indexed condition, and to 2 interventions — of which Corticosteroid Injection is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06550024 reports 8 study locations spanning 7 distinct geographic areas — top geographies include Other, Alabama, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06550024 about?

NCT06550024 is a clinical study titled "SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization". An open label, prospective, two-arm, multicenter, randomized controlled trial comparing SakuraBead genicular artery embolization (GAE) with a control (corticosteroid injection).

What is the current status of trial NCT06550024?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 89 participants. The study started on 2024-11-28. Estimated completion is 2028-10.

What conditions does trial NCT06550024 study?

This clinical trial studies the following conditions: Osteoarthritis, Arthritis, Osteo Arthritis Knee, Musculoskeletal Diseases, Rheumatic Diseases. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06550024?

The interventions under investigation include: Corticosteroid Injection (DRUG), SakuraBead Resorbable Microspheres (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06550024?

This trial is sponsored by CrannMed, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06550024 being conducted?

This trial has 8 study locations across Alabama, California, Florida, North Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial